DOCSLIB.ORG

Nutrient Health and EROEN Compounds Resegsterixsteextics: Production * Gets Cartrai, Agairaxxxix

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nutrient Health and EROEN Compounds Resegsterixsteextics: Production * Gets Cartrai, Agairaxxxix US 2011 O153221A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0153221 A1 Stefanon et al. (43) Pub. Date: Jun. 23, 2011 (54) DIAGNOSTIC SYSTEM FOR SELECTING (52) U.S. Cl. .......................................................... 702/19 NUTRITION AND PHARMACOLOGICAL PRODUCTS FOR ANIMALS (57) ABSTRACT (76) Inventors: Bruno Stefanon, Martignacco (IT): W.Year Jean Dodds.Odds, Santa Monica,IVIon1ca, CA An analysis of the profile of a non-human animal comprises: a) providing a genotypic database to the species of the non (21) Appl. No.: 12/927,769 human animal Subject or a selected group of the species; b obtaining animal data; c) correlating the database of a) with (22) Filed:1-1. Nov. 19, 2010 the data ofb) to determinea relationshipp between the database of a) and the data of b); c) determining the profile of the Related U.S. Application Data animal based on the correlating step; and d) determining a (63)63) ContinuationConti offaroplication application No. 12/316.824,:4'. filed'O geneticmolecular profile dietary based signature on the being molecular a variation dietary of signature, expression the of Dec. 16, 2008, now Pat. No. 7,873,482. a set of genes which may differ for the genotype of each O O animal or a group of animals Nutrition and pharmalogical Publication Classification assessments are made. Reporting the determination is by the (51) Int. Cl. Internet, and payment for the report is obtained through the G06F 9/00 (2011.01) Internet. 38s. 4 gas registics, $88's *.icisixxxiiserscies: 8 texrigixi exsix * processire statisy • Essex: 88& goEffect onXXXXWWYYX Nutrient health and EROEN Compounds resegsterixsteextics: production * gets cartrai, agairaxxxix. * exyxe regaia2: trapart regriasis xixe: 8x pxgixexactix Patent Application Publication Jun. 23, 2011 Sheet 1 of 23 US 2011/O153221 A1 s:----------- 388. •ges: 8gxiaixas, 888's awaaaaaaa-awawww.www.www.wow. RNix 4 gassissists &ast: Effect an Nutrient health and Compounds production *ggae extisai, signat:838sissists. 8xys regaixties *ixxiiixt: sixtifica: textgers registic:8 siege:::::sixts ris, it Patent Application Publication Jun. 23, 2011 Sheet 2 of 23 US 2011/O153221 A1 consumption xxxixitxss seix: {xesetix waxixxiiity 88.8.xxis 8888S FIG. 2 Betrospective: * &gsix 8xxxx 88.888ssassissaxss is $8: xx8sixigextick - - - - - - -8:grassisix: - - - - - - - - - - - a w-vs. www.aw aw-------------- - - - - - - - - - - - - - - - - - - ..., - - - - - - - - * Nessessies'. Sessie. SS s ^^ respective: y - * 3x3x3x: Scie:8 ^ y * s & 8x88:x: xxxx 8. A * °, s: - ^. : ^ *... ...-- Nigexia Sigraisire F.G. 3 Patent Application Publication Jun. 23, 2011 Sheet 3 of 23 US 2011/O153221 A1 wo REFERENCE AIASE TARGE DATASET GENotype GENOYE AND F MCTIONA. {ξ) ix{{8;& six838 {Ei{{C} { 38° 38' 88888.8. NORMAL (HEALTHY) ANMALS {{N-EA-Y AN8A.S kiki AASE; aaaaaaaaaaaaaaaaaaaaassssssssss-Xxxswaxxxwwaaaaaaa-X-X-X-X-XM Patent Application Publication Jun. 23, 2011 Sheet 4 of 23 US 2011/O153221 A1 ANIMA. FOR which NuTRENT NEEDS TO 8: ETER8:8EE EETERMINE FJNCT08A. &ENO ic PROFREBY DNA, 88A & Ai.Y838 &.g., 88CREAR8AY X------------------------- p 8888&E&C& EixãSE; A&E six;s&E C{}^33i:88-888-A. {8:38:88-888. 3&Noxic pBOF.&S -> GExoxic PROF.E FOR i8CR&Ai-8A.E-Y} (ABNC888&fux-SA.i-Y) ------------------------------------------------ www.wawwowswwwowswwww.--- NuTREEN DATASET CONTAKS v ARABLE axx-xx-xx-xx-xx-x-sesssssss EFEC's OF Nut REEN; sess {{ij}^{{IS N GENOMC381AN FJNCE:ONA. PROrities of (388&Y:s ax Aiyas with iEEREN &ExOYpsis: 8EN: Y }}s S8. pA -3.3GY OF THE AN8A. 88: loatan : 888:8 E:: K - 8-3A&EC: 88.8 (888. Nui RiENT Asia. £ASE -...-- EENTFY ; :ESREC N88N ...- ESRES NikiEx; --------------------------------------- Patent Application Publication Jun. 23, 2011 Sheet 7 of 23 US 2011/O153221 A1 Patent Application Publication Jun. 23, 2011 Sheet 8 of 23 US 2011/O153221 A1 8-8-8Ai-8 ES 8A:- - at ; Akivia. 88.8. xxiii.;&S {{ {{k{{* g ::$3S E888; Seiy ξ YSS Of FuhitoxA 3ENO8: 88: 88:8. AA&E x8 (38A. FOR8 it. A two FIG. 6A Patent Application Publication Jun. 23, 2011 Sheet 10 of 23 US 2011/O153221 A1 ki.exes (ex: xxi-xxcessor -i. Y Patent Application Publication Jun. 23, 2011 Sheet 11 of 23 US 2011/O153221 A1 s --------X-X -, -, --- Swx-x-xx-xx-xx-xx-ax-Xassassssssssssss Patent Application Publication Jun. 23, 2011 Sheet 12 of 23 US 2011/O153221 A1 8xxix:8 sigrate of 888 &g:::::it: 888 &ig 888 x carcissis Patent Application Publication Jun. 23, 2011 Sheet 13 of 23 US 2011/O153221 A1 X. : s 3. 3. - s: sa --- wr: -8. 2. & & & & X -- : s: s s : E. 8: 8 s: 8: w se: x- :- . 8 s: s s: > 3. & : & :: & : s i 3. 3. 8:3: 2:3 83.3 -i. Patent Application Publication Jun. 23, 2011 Sheet 14 of 23 US 2011/O153221 A1 pi, if Patent Application Publication Jun. 23, 2011 Sheet 15 of 23 US 2011/015.3221 A1 2K3. IL2K8. ... O R IL1RAP RN K. II.4. { IL3RA NC N INEA-2 x xt 3 Ni 8 x 333 x RS 3C NERSA NKS 83 Patent Application Publication Jun. 23, 2011 Sheet 16 of 23 US 2011/O153221 A1 {x ::: 333. $3:33 383 Sis: :::::: {3x3 {3. & 38.3 {Yg: {83. {fg} : ; : : ***... :is ; 3.; ; $838. 8.33 EY:...i. {Ski (S: , S.: 3.x. 38: {fi:3: Sä. Patent Application Publication Jun. 23, 2011 Sheet 17 of 23 US 2011/O153221 A1 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&& Patent Application Publication Jun. 23, 2011 Sheet 18 of 23 US 2011/O153221 A1 Patent Application Publication Jun. 23, 2011 Sheet 19 of 23 US 2011/O153221 A1 rom:1||o?.||->| Patent Application Publication Jun. 23, 2011 Sheet 20 of 23 US 2011/O153221 A1 s: s: : w Patent Application Publication Jun. 23, 2011 Sheet 21 of 23 US 2011/O153221 A1 ***********************************************&&&&&& ?§§§§§§333% §§§§ §§§§§§ §§§§ ????????? | Patent Application Publication Jun. 23, 2011 Sheet 22 of 23 US 2011/O153221 A1 Patent Application Publication Jun. 23, 2011 Sheet 23 of 23 US 2011/O153221 A1 A8(8&City 88.88 *::: Sis. S-8. Aces :8: i8S$ iii. ACCESS 88:x: ki::::::::: S$80 Ef 8::::::::: 8:SCE US 2011/O153221 A1 Jun. 23, 2011 DAGNOSTIC SYSTEM FOR SELECTING methods have also been proposed, but these are not definitive NUTRITION AND PHARMACOLOGICAL when applied to different animals or species of animals. PRODUCTS FOR ANIMALS 0011. The fields of nutrigenetics and nutrigenomics have opened the way in humans for “personalized nutrition', as BACKGROUND pharmacogenetics and pharmacogenomics have led to the concept of “personalized medicine” and "designer drugs'. 0001. This disclosure is concerned with animal nutrition Similar scientific advances and concepts are being applied to diagnosis. More particularly the disclosure is directed to the the nutrigenetics and nutrigenomics of animals. In other testing and diagnosis of genetic issues relating to nutrition words, by understanding animal nutritional needs, animal issues and disorders of companion animals, for instance dogs nutritional status, animal physiological or pathophysiological and cats. conditions, animal functional genomic profiles and animal 0002 Further this disclosure relates to a method, system genotypes, nutrigenetics and nutrigenomics should enable and apparatus for the management of nutrition assessment in better management or control of the health and well-being of relation to animals worldwide. In particular, the disclosure individual animals or a group of animals by precisely match relates to a bioinformatics system and its implementation in ing their nutrient needs or dietary composition with their relation to animal biological, genetic and nutrition data. unique genetic makeup. 0003 More specifically the disclosure is directed to ani (0012 “DNA polymorphisms” (i.e. SNPs) have been used malnutrition diagnosis and care, animal well-being and nutri for animal genotyping, in order to identify breed characteris tion, and methods and systems for enhanced determination of tics, or disease Susceptibility, or have been applied to group these factors. animal populations by one or more phenotypic traits accord 0004 Breeders, owners, and caregivers of animals which ing to the frequency of a set of geneticalleles. can be companions, such as dogs, cats, horses, farm, food, or 0013 The “functional genomic profile' is another tech Zoo animals, and wildlife, have a need to understand the nique used to identify breed characteristics, or disease Sus nutrition and biological attributes, and related genetic ceptibility or is applied to group animal populations or an makeup and disorder background, particularly in relation to individual animal one or more by several phenotypic traits nutritional features. according to the pattern of gene expressions (genomics), or 0005 Substantial investments in time, effort and financial protein expressions (proteomics) or metabolites (metabolo resources are made by the breeders, owners, and caregivers of mics). these animals, particularly purebred animals, to characterize 0014. The specific interaction between the nutritional their nutrition state. There is also a need to conduct periodic environment and the genome of an individual has been termed comprehensive nutrition assessments of animals. the molecular dietary signature of that individual 0006. The probability that an individual animal will 0015. It is important for nutritionists or other animal food develop a specific nutrition-related condition in its lifetime is professionals to prescribe or recommend nutrient needs or a product of complex interactions between its genetic diets on the basis of more precise knowledge of how nutrients makeup, environmental influences including diet, and agents or food components interact at the level of the genome, where of disease (e.g., chemical, physical, or biological) that the these constituents act by “up- or down-regulating a set of animal encounters. target genes. Animal nutritionists or other animal food pro 0007. The physical attributes and other descriptive and fessionals should design nutrients or foods tailored to the nutrition assessment information are generally termed in this genome or genomic profile or to prescribe or recommend the application as the phenotypic information.
Load more

Recommended publications
  • Wo 2010/075007 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075007 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) G06F 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/067757 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 11 December 2009 ( 11.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12/3 16,877 16 December 2008 (16.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): DODDS, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, W., Jean [US/US]; 938 Stanford Street, Santa Monica, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, CA 90403 (US).
    [Show full text]
  • Transcriptional Regulation of RKIP in Prostate Cancer Progression
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Sciences Transcriptional Regulation of RKIP in Prostate Cancer Progression Submitted by: Sandra Marie Beach In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Sciences Examination Committee Major Advisor: Kam Yeung, Ph.D. Academic William Maltese, Ph.D. Advisory Committee: Sonia Najjar, Ph.D. Han-Fei Ding, M.D., Ph.D. Manohar Ratnam, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: May 16, 2007 Transcriptional Regulation of RKIP in Prostate Cancer Progression Sandra Beach University of Toledo ACKNOWLDEGMENTS I thank my major advisor, Dr. Kam Yeung, for the opportunity to pursue my degree in his laboratory. I am also indebted to my advisory committee members past and present, Drs. Sonia Najjar, Han-Fei Ding, Manohar Ratnam, James Trempe, and Douglas Pittman for generously and judiciously guiding my studies and sharing reagents and equipment. I owe extended thanks to Dr. William Maltese as a committee member and chairman of my department for supporting my degree progress. The entire Department of Biochemistry and Cancer Biology has been most kind and helpful to me. Drs. Roy Collaco and Hong-Juan Cui have shared their excellent technical and practical advice with me throughout my studies. I thank members of the Yeung laboratory, Dr. Sungdae Park, Hui Hui Tang, Miranda Yeung for their support and collegiality. The data mining studies herein would not have been possible without the helpful advice of Dr. Robert Trumbly. I am also grateful for the exceptional assistance and shared microarray data of Dr.
    [Show full text]
  • CD56+ T-Cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients
    CD56+ T-cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients Institute of Infection and Global Health Department of Clinical Infection, Microbiology and Immunology Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy by Mazen Mohammed Almehmadi December 2014 - 1 - Abstract Human T cells expressing CD56 are capable of tumour cell lysis following activation with interleukin-2 but their role in viral immunity has been less well studied. The work described in this thesis aimed to investigate CD56+ T-cells in relation to cytomegalovirus infection in healthy subjects and kidney transplant patients (KTPs). Proportions of CD56+ T cells were found to be highly significantly increased in healthy cytomegalovirus-seropositive (CMV+) compared to cytomegalovirus-seronegative (CMV-) subjects (8.38% ± 0.33 versus 3.29%± 0.33; P < 0.0001). In donor CMV-/recipient CMV- (D-/R-)- KTPs levels of CD56+ T cells were 1.9% ±0.35 versus 5.42% ±1.01 in D+/R- patients and 5.11% ±0.69 in R+ patients (P 0.0247 and < 0.0001 respectively). CD56+ T cells in both healthy CMV+ subjects and KTPs expressed markers of effector memory- RA T-cells (TEMRA) while in healthy CMV- subjects and D-/R- KTPs the phenotype was predominantly that of naïve T-cells. Other surface markers, CD8, CD4, CD58, CD57, CD94 and NKG2C were expressed by a significantly higher proportion of CD56+ T-cells in healthy CMV+ than CMV- subjects. Functional studies showed levels of pro-inflammatory cytokines IFN-γ and TNF-α, as well as granzyme B and CD107a were significantly higher in CD56+ T-cells from CMV+ than CMV- subjects following stimulation with CMV antigens.
    [Show full text]
  • Systems Analysis Implicates WAVE2&Nbsp
    JACC: BASIC TO TRANSLATIONAL SCIENCE VOL.5,NO.4,2020 ª 2020 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/). PRECLINICAL RESEARCH Systems Analysis Implicates WAVE2 Complex in the Pathogenesis of Developmental Left-Sided Obstructive Heart Defects a b b b Jonathan J. Edwards, MD, Andrew D. Rouillard, PHD, Nicolas F. Fernandez, PHD, Zichen Wang, PHD, b c d d Alexander Lachmann, PHD, Sunita S. Shankaran, PHD, Brent W. Bisgrove, PHD, Bradley Demarest, MS, e f g h Nahid Turan, PHD, Deepak Srivastava, MD, Daniel Bernstein, MD, John Deanfield, MD, h i j k Alessandro Giardini, MD, PHD, George Porter, MD, PHD, Richard Kim, MD, Amy E. Roberts, MD, k l m m,n Jane W. Newburger, MD, MPH, Elizabeth Goldmuntz, MD, Martina Brueckner, MD, Richard P. Lifton, MD, PHD, o,p,q r,s t d Christine E. Seidman, MD, Wendy K. Chung, MD, PHD, Martin Tristani-Firouzi, MD, H. Joseph Yost, PHD, b u,v Avi Ma’ayan, PHD, Bruce D. Gelb, MD VISUAL ABSTRACT Edwards, J.J. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(4):376–86. ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2020.01.012 JACC: BASIC TO TRANSLATIONALSCIENCEVOL.5,NO.4,2020 Edwards et al. 377 APRIL 2020:376– 86 WAVE2 Complex in LVOTO HIGHLIGHTS ABBREVIATIONS AND ACRONYMS Combining CHD phenotype–driven gene set enrichment and CRISPR knockdown screening in zebrafish is an effective approach to identifying novel CHD genes.
    [Show full text]
  • Multi-Targeted Mechanisms Underlying the Endothelial Protective Effects of the Diabetic-Safe Sweetener Erythritol
    Multi-Targeted Mechanisms Underlying the Endothelial Protective Effects of the Diabetic-Safe Sweetener Erythritol Danie¨lle M. P. H. J. Boesten1*., Alvin Berger2.¤, Peter de Cock3, Hua Dong4, Bruce D. Hammock4, Gertjan J. M. den Hartog1, Aalt Bast1 1 Department of Toxicology, Maastricht University, Maastricht, The Netherlands, 2 Global Food Research, Cargill, Wayzata, Minnesota, United States of America, 3 Cargill RandD Center Europe, Vilvoorde, Belgium, 4 Department of Entomology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California, United States of America Abstract Diabetes is characterized by hyperglycemia and development of vascular pathology. Endothelial cell dysfunction is a starting point for pathogenesis of vascular complications in diabetes. We previously showed the polyol erythritol to be a hydroxyl radical scavenger preventing endothelial cell dysfunction onset in diabetic rats. To unravel mechanisms, other than scavenging of radicals, by which erythritol mediates this protective effect, we evaluated effects of erythritol in endothelial cells exposed to normal (7 mM) and high glucose (30 mM) or diabetic stressors (e.g. SIN-1) using targeted and transcriptomic approaches. This study demonstrates that erythritol (i.e. under non-diabetic conditions) has minimal effects on endothelial cells. However, under hyperglycemic conditions erythritol protected endothelial cells against cell death induced by diabetic stressors (i.e. high glucose and peroxynitrite). Also a number of harmful effects caused by high glucose, e.g. increased nitric oxide release, are reversed. Additionally, total transcriptome analysis indicated that biological processes which are differentially regulated due to high glucose are corrected by erythritol. We conclude that erythritol protects endothelial cells during high glucose conditions via effects on multiple targets.
    [Show full text]
  • Transcriptional Regulation Differs in Affected Facioscapulohumeral Muscular Dystrophy Patients Compared to Asymptomatic Related Carriers
    University of Massachusetts Medical School eScholarship@UMMS Wellstone Center for FSHD Publications Wellstone Center for FSHD 2009-04-14 Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers Patricia Arashiro University of Sao Paulo Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/wellstone_pubs Part of the Cell Biology Commons, Developmental Biology Commons, Molecular Biology Commons, Molecular Genetics Commons, Musculoskeletal Diseases Commons, and the Nervous System Diseases Commons Repository Citation Arashiro P, Eisenberg I, Kho AT, Cerqueira AM, Canovas M, Silva HC, Pavanello RC, Verjovski-Almeida S, Kunkel LM, Zatz M. (2009). Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Wellstone Center for FSHD Publications. https://doi.org/10.1073/pnas.0901573106. Retrieved from https://escholarship.umassmed.edu/ wellstone_pubs/18 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Wellstone Center for FSHD Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers Patricia Arashiroa, Iris Eisenbergb, Alvin T. Khoc, Antonia M. P. Cerqueiraa, Marta
    [Show full text]
  • Bioinformatics Analyses of Genomic Imprinting
    Bioinformatics Analyses of Genomic Imprinting Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Barbara Hutter Saarbrücken 2009 Tag des Kolloquiums: 08.12.2009 Dekan: Prof. Dr.-Ing. Stefan Diebels Berichterstatter: Prof. Dr. Volkhard Helms Priv.-Doz. Dr. Martina Paulsen Vorsitz: Prof. Dr. Jörn Walter Akad. Mitarbeiter: Dr. Tihamér Geyer Table of contents Summary________________________________________________________________ I Zusammenfassung ________________________________________________________ I Acknowledgements _______________________________________________________II Abbreviations ___________________________________________________________ III Chapter 1 – Introduction __________________________________________________ 1 1.1 Important terms and concepts related to genomic imprinting __________________________ 2 1.2 CpG islands as regulatory elements ______________________________________________ 3 1.3 Differentially methylated regions and imprinting clusters_____________________________ 6 1.4 Reading the imprint __________________________________________________________ 8 1.5 Chromatin marks at imprinted regions___________________________________________ 10 1.6 Roles of repetitive elements ___________________________________________________ 12 1.7 Functional implications of imprinted genes _______________________________________ 14 1.8 Evolution and parental conflict ________________________________________________
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon Et Al
    US007873482B2 (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon et al. (45) Date of Patent: Jan. 18, 2011 (54) DIAGNOSTIC SYSTEM FOR SELECTING 6,358,546 B1 3/2002 Bebiak et al. NUTRITION AND PHARMACOLOGICAL 6,493,641 B1 12/2002 Singh et al. PRODUCTS FOR ANIMALS 6,537,213 B2 3/2003 Dodds (76) Inventors: Bruno Stefanon, via Zilli, 51/A/3, Martignacco (IT) 33035: W. Jean Dodds, 938 Stanford St., Santa Monica, (Continued) CA (US) 90403 FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 WO WO99-67642 A2 12/1999 U.S.C. 154(b) by 158 days. (21)21) Appl. NoNo.: 12/316,8249 (Continued) (65) Prior Publication Data Swanson, et al., “Nutritional Genomics: Implication for Companion Animals'. The American Society for Nutritional Sciences, (2003).J. US 2010/O15301.6 A1 Jun. 17, 2010 Nutr. 133:3033-3040 (18 pages). (51) Int. Cl. (Continued) G06F 9/00 (2006.01) (52) U.S. Cl. ........................................................ 702/19 Primary Examiner—Edward Raymond (58) Field of Classification Search ................... 702/19 (74) Attorney, Agent, or Firm Greenberg Traurig, LLP 702/23, 182–185 See application file for complete search history. (57) ABSTRACT (56) References Cited An analysis of the profile of a non-human animal comprises: U.S. PATENT DOCUMENTS a) providing a genotypic database to the species of the non 3,995,019 A 1 1/1976 Jerome human animal Subject or a selected group of the species; b) 5,691,157 A 1 1/1997 Gong et al.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Mclean, Chelsea.Pdf
    COMPUTATIONAL PREDICTION AND EXPERIMENTAL VALIDATION OF NOVEL MOUSE IMPRINTED GENES A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Chelsea Marie McLean August 2009 © 2009 Chelsea Marie McLean COMPUTATIONAL PREDICTION AND EXPERIMENTAL VALIDATION OF NOVEL MOUSE IMPRINTED GENES Chelsea Marie McLean, Ph.D. Cornell University 2009 Epigenetic modifications, including DNA methylation and covalent modifications to histone tails, are major contributors to the regulation of gene expression. These changes are reversible, yet can be stably inherited, and may last for multiple generations without change to the underlying DNA sequence. Genomic imprinting results in expression from one of the two parental alleles and is one example of epigenetic control of gene expression. So far, 60 to 100 imprinted genes have been identified in the human and mouse genomes, respectively. Identification of additional imprinted genes has become increasingly important with the realization that imprinting defects are associated with complex disorders ranging from obesity to diabetes and behavioral disorders. Despite the importance imprinted genes play in human health, few studies have undertaken genome-wide searches for new imprinted genes. These have used empirical approaches, with some success. However, computational prediction of novel imprinted genes has recently come to the forefront. I have developed generalized linear models using data on a variety of sequence and epigenetic features within a training set of known imprinted genes. The resulting models were used to predict novel imprinted genes in the mouse genome. After imposing a stringency threshold, I compiled an initial candidate list of 155 genes.
    [Show full text]
  • Supporting Information
    Supporting Information Collin et al. 10.1073/pnas.1220864110 SI Materials and Methods Mutation Analysis of PASK and ZNF408. The two candidate variants Human Subjects. A detailed clinical description of familial exudative that were left after linkage and exome analysis were analyzed in vitreoretinopathy (FEVR) family W05-215 has been reported family W05-215 with Sanger sequencing of exon 6 of proline- previously (1), and clinical details of the affected individuals alanine-rich ste20-related kinase (PASK) and exon 5 of zinc studied using next-generation sequencing (NGS) (III:5 and V:2) finger protein 408 (ZNF408). Primer sequences are available are summarized below. Eight affected individuals, three un- on request. The presence of these two changes in additional affected individuals, and three spouses participated in the ge- Dutch FEVR probands and 110 control individuals was ana- netic analysis (Fig. S1A). After linkage and exome sequencing lyzed via restriction fragment length polymorphism analysis, analysis were performed, three additional affected relatives using AflIII for the c.791dup change in PASK and SfaNI for the (IV:10, IV:11, and V:7) were sampled. Clinical details of the c.1363C>T change in ZNF408. All exons and intron–exon two individuals with FEVR from family W05-220 (IV:3 and boundaries of ZNF408 were amplified under standard PCR V:2) are summarized below. Furthermore, 132 individuals with conditions using primers that are available on request. Sanger FEVR (8 from The Netherlands, 64 from the United Kingdom, sequence analysis was performed with the ABI PRISM Big Dye 55 from Japan, and 5 from Switzerland) participated in this Terminator Cycle Sequencing V2.0 Ready Reaction Kit and study, along with 110 ethnically matched Dutch and 191 eth- an ABI PRISM 3730 DNA analyzer (Applied Biosystems).
    [Show full text]
  • Atlas Journal
    Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 12, Number 6, Nov-Dec 2008 Previous Issue / Next Issue Genes BCL8 (B-cell CLL/lymphoma 8) (15q11). Silvia Rasi, Gianluca Gaidano. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 781-784. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/BCL8ID781ch15q11.html CDC25A (Cell division cycle 25A) (3p21). Dipankar Ray, Hiroaki Kiyokawa. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 785-791. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CDC25AID40004ch3p21.html CDC73 (cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)) (1q31.2). Leslie Farber, Bin Tean Teh. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 792-797. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CDC73D181ch1q31.html EIF3C (eukaryotic translation initiation factor 3, subunit C) (16p11.2). Daniel R Scoles. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 798-802. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/EIF3CID44187ch16p11.html ELAC2 (elaC homolog 2 (E. coli)) (17p11.2). Yang Chen, Sean Tavtigian, Donna Shattuck. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 803-806. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/ELAC2ID40437ch17p11.html FOXM1 (forkhead box M1) (12p13). Jamila Laoukili, Monica Alvarez Fernandez, René H Medema.
    [Show full text]